Uncategorized
Rho kinase inhibitor non-inferior to timolol in two phase 3 studies
FORT LAUDERDALE, Fla. — A small-molecule Rho kinase inhibitor and norepinephrine transporter was non-inferior to timolol in two clinical studies, according to a scientific poster presented here. Jason Bacharach, MD, presented results of the phase 3 ROCKET 1 and ROCKET 2 studies at the American Glaucoma Society meeting.